News

Digital medical services platform Teladoc Health (NYSE:TDOC) reported Q1 CY2026 results beating Wall Street’s revenue expectations, but sales fell by 2.5% year on year to $613.8 million. Revenue guidance for the full year exceeded analysts’ estimates, but next quarter’s guidance of $611.5 million was less impressive, coming in 2% below expectations. Its GAAP loss of $0.36 per share was 3.6% below analysts’ consensus estimates.

Hims & Hers and Teladoc Health are taking different paths in digital health, but which stock offers stronger upside now? Let's dive in.

Teladoc Health, Inc. recently reported first-quarter 2026 results, with sales of US$613.85 million versus US$629.37 million a year earlier and a net loss of US$63.84 million compared with US$93.01 million. While revenue slipped, the reduced net loss and lower loss per share highlight Teladoc’s efforts to tighten operations and move closer to breakeven. We’ll now examine how Teladoc’s lower quarterly net loss, despite softer revenue, may influence its existing investment narrative and...

Moby summary of Teladoc Health, Inc.'s Q1 2026 earnings call

Teladoc Health Inc (TDOC) reports robust revenue growth and strategic advancements in AI and insurance, despite challenges in cash flow and business model shifts.

While the top- and bottom-line numbers for Teladoc (TDOC) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Teladoc (TDOC) delivered earnings and revenue surprises of -13.82% and +0.25%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Digital medical services platform Teladoc Health (NYSE:TDOC) announced better-than-expected revenue in Q1 CY2026, but sales fell by 2.5% year on year to $613.8 million. Revenue guidance for the full year exceeded analysts’ estimates, but next quarter’s guidance of $611.5 million was less impressive, coming in 2% below expectations. Its GAAP loss of $0.36 per share was 4.7% below analysts’ consensus estimates.